In spite of various headwinds, a strong uptick in surgical procedures and business activities in March was the slingshot effect needed to propel the US Orthobio Market into double-digit percentage growth for Q121.
In spite of the headwinds from a resurgence of COVID-19 cases in Q420 that spilled over to the early part of Q121 and winter storms of historical proportions in February, a strong uptick in elective surgical procedures in March was the slingshot effect the US Orthobio Market needed to propel it.
Among the many topics covered in detail in our comprehensive Q121 US Orthobio Market Recap* are:
- Complete Q121 US Orthobio Market Overview and Highlights
- SmartTRAK's Expert Analysis and Insights
- Notable Regulatory Developments in Q121
- Segment Results and Key Market Competitors in:
- US Bone Replacement
- US Cartilage Replacement
- US Soft Tissue Replacement
-
US Meniscus Replacement
Along with an uptick in the number of elective procedures, other factors influencing growth in Q121 included, among others, new product introductions, athletes experiencing a higher rate of injury upon return to sport after COVID-19 pandemic isolation and ...
*The entire unedited article and these links can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.
SmartTRAK has recently expanded its coverage to include five new modules. Click to see details of all the exciting new additions to the SmartTRAK platform in 2021.
